BOCHK Asset Management Ltd Acquires 37,900 Shares of Pfizer Inc. $PFE

Key Points

• BOCHK Asset Management Ltd sharply increased its Pfizer stake by 2,915.4%, buying 37,900 shares in Q4 to hold 39,200 shares worth about $976,000.
• Pfizer beat Q4 expectations with $0.66 EPS (vs. $0.57 est.) and revenue of $17.56 billion (vs. $16.93 billion), and analysts project about 2.95 EPS for the current year.
• Analyst sentiment is mixed: the consensus rating is Hold with an average price target of $28.10, though firms range from HSBC's $32 Buy to Barclays/RBC underweight/sell calls.

BOCHK Asset Management Ltd raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2,915.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,200 shares of the biopharmaceutical company's stock after acquiring an additional 37,900 shares during the quarter. BOCHK Asset Management Ltd's holdings in Pfizer were worth $976,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank grew its stake in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Pfizer by 21.1% in the second quarter. NewEdge Advisors LLC now owns 560,673 shares of the biopharmaceutical company's stock valued at $13,591,000 after buying an additional 97,789 shares in the last quarter. Finally, Frisch Financial Group Inc. grew its stake in shares of Pfizer by 16.9% in the second quarter. Frisch Financial Group Inc. now owns 41,869 shares of the biopharmaceutical company's stock valued at $1,015,000 after buying an additional 6,051 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.9%

PFE stock opened at $27.23 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a fifty day moving average price of $27.19 and a two-hundred day moving average price of $25.91. Pfizer Inc. has a one year low of $21.08 and a one year high of $28.75. The stock has a market cap of $154.84 billion, a price-to-earnings ratio of 20.02 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analysts' expectations of $16.93 billion. During the same period in the previous year, the business posted $0.63 earnings per share. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on PFE shares. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. Barclays assumed coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an "underweight" rating and a $25.00 target price for the company. Daiwa Securities Group downgraded Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target for the company. in a report on Thursday, February 12th. Finally, Royal Bank Of Canada assumed coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an "underperform" rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $28.10.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s deep and diversified oncology portfolio and pipeline, which could support longer-term revenue growth and investor sentiment ahead of quarterly results. How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: MarketWatch noted Pfizer stock rose Wednesday (while still underperforming the broader market), signaling intermittent buying interest that can counterbalance downside pressure from analyst moves. Pfizer Inc. stock rises Wednesday, still underperforms market
• Neutral Sentiment: Pfizer invited shareholders to a virtual Annual Meeting on April 23, 2026 — a standard corporate governance event that may include Q&A but is unlikely to move the stock materially by itself. Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
• Neutral Sentiment: ResearchAndMarkets published a biopharmaceutical CXO market report that cites major players including Pfizer; this industry-level report highlights outsourcing and supply-chain trends but has indirect impact on Pfizer’s near-term stock moves. $1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032
• Neutral Sentiment: Pfizer Limited announced a special window for dematerialisation of physical shares (local/regulatory matter) — relevant to regional investors but not material to NYSE-listed PFE’s valuation. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: Pfizer CEO Albert Bourla commented on U.S./European academic competitiveness vs. China — a strategic/PR item reflecting management views on R&D policy rather than an immediate stock catalyst. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Negative Sentiment: Bank of America cut its price target on PFE from $27 to $26 and set a Neutral rating — this reduces upside expectations and can apply downward pressure on the stock. Benzinga
• Negative Sentiment: RBC Capital reaffirmed a Sell rating on Pfizer, reinforcing bearish analyst sentiment and adding to near-term selling pressure from income-oriented or risk-averse investors. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
• Negative Sentiment: Yahoo Finance ran a piece explaining why Pfizer shares tumbled earlier in the week — investors should read it for details on the drivers of recent volatility (analyst moves, trading flows or company-specific news). Why Pfizer Stock Tumbled on Tuesday

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.